miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells

Cancer Res. 2014 Aug 1;74(15):4183-95. doi: 10.1158/0008-5472.CAN-14-0404. Epub 2014 Jun 5.

Abstract

microRNA-128 (miR128) is reduced in prostate cancer relative to normal/benign prostate tissues, but causal roles are obscure. Here we show that exogenously introduced miR128 suppresses tumor regeneration in multiple prostate cancer xenograft models. Cancer stem-like cell (CSC)-associated properties were blocked, including holoclone and sphere formation as well as clonogenic survival. Using a miR128 sensor to distinguish cells on the basis of miR128 expression, we found that miR128-lo cells possessed higher clonal, clonogenic, and tumorigenic activities than miR128-hi cells. miR128 targets the stem cell regulatory factors BMI-1, NANOG, and TGFBR1, the expression of which we found to vary inversely with miR128 expression in prostate cancer stem/progenitor cell populations. In particular, we defined BMI-1 as a direct and functionally relevant target of miR128 in prostate cancer cells, where these genes were reciprocally expressed and exhibited opposing biological functions. Our results define a tumor suppressor function for miR128 in prostate cancer by limiting CSC properties mediated by BMI-1 and other central stem cell regulators, with potential implications for prostate cancer gene therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Genetic Therapy
  • Humans
  • Male
  • Mice, Inbred NOD
  • Mice, SCID
  • MicroRNAs / administration & dosage*
  • MicroRNAs / genetics
  • Neoplastic Stem Cells / pathology
  • Polycomb Repressive Complex 1 / antagonists & inhibitors*
  • Polycomb Repressive Complex 1 / genetics
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Prostatic Neoplasms, Castration-Resistant / pathology
  • Prostatic Neoplasms, Castration-Resistant / therapy
  • Transfection
  • Xenograft Model Antitumor Assays

Substances

  • BMI1 protein, human
  • MIRN128 microRNA, human
  • MicroRNAs
  • Polycomb Repressive Complex 1